ATTAIN-MAINTAIN Trial Shows Orforglipron Maintains Weight Loss After Injectable Switch
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
#clinical-trial
2 stories
Icotrokinra Achieves Complete Skin Clearance Through Week 52 in Trials
Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.